COMPASS Pathways plc announced today that it has been granted its fifth patent by the US Patent and Trademark Office.
Category Press Release
Country United Kingdom
Companies Featured
COMPASS PathwaysCOMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.